Work

789P Translational study and preliminary clinical trial of WX390 monotherapy in cancers with concurrence of PIK3CA and ARID1A mutations

Year: 2024

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.2149

Authors: J. Li, X. Wu, G. Li, A. Huang, D. Wang, Q. Chen, L. Wang, R. An, Y. Huang, Y. Kang, X. Cheng, B. Li, G. Zhu, F. You, Y. Qi, Y. Li, J. Wang

Institutions: Fudan University Shanghai Cancer Center, Wuhan Union Hospital, Huazhong University of Science and Technology, Chongqing University, Chongqing Cancer Hospital, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Henan Cancer Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Hubei Cancer Hospital, Shanghai Medical College of Fudan University, Fudan University, Obstetrics and Gynecology Hospital of Fudan University, Guilin Medical University, Hunan Cancer Hospital

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Pfizer, AstraZeneca, F. Hoffmann-La Roche, Regeneron Pharmaceuticals, Novocure, Les Laboratories Pierre Fabre, Clovis Oncology, Deciphera Pharmaceuticals, Mersana Therapeutics, Myriad Genetics, Seagen, Eisai, PharmaMar, Daiichi Sankyo Europe

OpenAlex ID: W4402558703

FWCI:

Cites:

Cited by:

Related to: 10